The Experts below are selected from a list of 1698 Experts worldwide ranked by ideXlab platform

Mao Ming-hui - One of the best experts on this subject based on the ideXlab platform.

  • Comparing the RTOG/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after I-125 seed brachytherapy for Parotid Gland Cancer
    BRACHYTHERAPY, 2017
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zhang Jie, Feng Zhien, Li Hua, Qin Li-zheng, Li Jian-hua, Huang Xin, Xing Ru-dong, Han Zheng-xue
    Abstract:

    PURPOSE: The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in Parotid Gland Cancer patients. METHODS AND MATERIALS: A total of 109 patients diagnosed with Parotid Gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100-120 Gy. After 6-24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria. The strength of correlation between the scores and the interobserver variability were calculated. RESULTS: Of 109 patients, 22.9% had telangiectasia; 78.9%, pigmentation; 28.4%, fibrosis; 4.6%, edema; 0.9%, ulceration; 37.6%, retraction and/or atrophy; 22.9%, sensation change; and 11%, scaliness and/or roughness. Compared with RTOG, LENT-SOMA criteria resulted in the upgrading of pigmentation in 17% of cases, the downgrading of all instances of telangiectasia and the downgrading of one instance of Grade 4 ulceration to Grade 3. Between the two scales, fibrosis and atrophy correlated well (Spearman p, 0.992, 0.986). An additional 229 side effects were observed using LENT-SOMA criteria. CONCLUSIONS: The LENT-SOMA scale was more accurate than the RTOG scale for the evaluation of late skin and subcutaneous toxicity. The downgrading of telangiectasia and upgrading of pigmentation with the LENT-SOMA scale reflected the patients' conditions better than the scores obtained with the RTOG scale. The assessment of fibrosis and atrophy correlated well between the two scales. The use of the sum of the individual scores of the LENT-SOMA is therefore advocated. The addition of decreased sweating and the removal of the alopecia (scalp) metric should be considered to standardize the reporting of late radiation morbidity. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.SCI(E)ARTICLE4,SI877-8831

  • The incidence of radioepidermitis and the dose-response relationship in Parotid Gland Cancer patients treated with 125I seed brachytherapy
    strahlentherapie und onkologie, 2015
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zheng Lei, Gao Hong, Zhang Jie, Liu Shu-ming, Huang Ming-wei, Shi Yan
    Abstract:

    Background We studied the incidence and dose-response relationship of radioepidermitis in Parotid Gland carcinoma patients treated with [I-125] seed brachytherapy in the hopes of designing an optimized pre-implant treatment plan that would reduce the incidence and severity of radioepidermitis in patients receiving this therapy. Patients and methods Between January 2007 and May 2010, 100 Parotid Gland Cancer patients were treated postoperatively with [I-125] seed brachytherapy. The matched peripheral dose (MPD) was 80-140 Gy, and [I-125] seed activity was 0.7-0.8 mCi. The mean dose delivered to the skin was calculated in the post-implant CT on day 0 following implantation. Grades of acute and late dermatitis were evaluated at 2, 6, 12, and 18 months post-implantation. Results Most patients experienced grade 0-2 acute and late skin side effects (86 and 97 %, respectively), though a small subset developed severe complications. Most grade 1-3 effects resolved within 6 months of implantation, though some grade 1-3 effects and all grade 4 effects remained unchanged throughout the 18-month follow-up period. Grade 3 and 4 effects were most prominent (75 and 25 %, respectively) with doses of 110-140 Gy; doses higher than 140 Gy produced only grade 4 effects. Conclusion [I-125] seed brachytherapy produced acceptable levels of acute and late radioepidermitis with a good clinical outcome. A mean dose under 100 Gy delivered to the skin was safe, though doses of 110-140 Gy should be given with caution and extra monitoring; doses greater than 140 Gy are dangerous and likely to produce grade 4-5 effects.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000347719800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701OncologyRadiology, Nuclear Medicine & Medical ImagingSCI(E)PubMed0ARTICLErszhang@126.com126-3319

Jianguo Zhang - One of the best experts on this subject based on the ideXlab platform.

  • comparing the rtog eortc and lent soma scoring systems for the evaluation of late skin toxicity after 125i seed brachytherapy for Parotid Gland Cancer
    Brachytherapy, 2017
    Co-Authors: Jie Zhang, Jianguo Zhang
    Abstract:

    Abstract Purpose The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in Parotid Gland Cancer patients. Methods and Materials A total of 109 patients diagnosed with Parotid Gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100–120 Gy. After 6–24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria. The strength of correlation between the scores and the interobserver variability were calculated. Results Of 109 patients, 22.9% had telangiectasia; 78.9%, pigmentation; 28.4%, fibrosis; 4.6%, edema; 0.9%, ulceration; 37.6%, retraction and/or atrophy; 22.9%, sensation change; and 11%, scaliness and/or roughness. Compared with RTOG, LENT-SOMA criteria resulted in the upgrading of pigmentation in 17% of cases, the downgrading of all instances of telangiectasia and the downgrading of one instance of Grade 4 ulceration to Grade 3. Between the two scales, fibrosis and atrophy correlated well (Spearman ρ, 0.992, 0.986). An additional 229 side effects were observed using LENT-SOMA criteria. Conclusions The LENT-SOMA scale was more accurate than the RTOG scale for the evaluation of late skin and subcutaneous toxicity. The downgrading of telangiectasia and upgrading of pigmentation with the LENT-SOMA scale reflected the patients' conditions better than the scores obtained with the RTOG scale. The assessment of fibrosis and atrophy correlated well between the two scales. The use of the sum of the individual scores of the LENT-SOMA is therefore advocated. The addition of decreased sweating and the removal of the alopecia (scalp) metric should be considered to standardize the reporting of late radiation morbidity.

Han Zheng-xue - One of the best experts on this subject based on the ideXlab platform.

  • Comparing the RTOG/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after I-125 seed brachytherapy for Parotid Gland Cancer
    BRACHYTHERAPY, 2017
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zhang Jie, Feng Zhien, Li Hua, Qin Li-zheng, Li Jian-hua, Huang Xin, Xing Ru-dong, Han Zheng-xue
    Abstract:

    PURPOSE: The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in Parotid Gland Cancer patients. METHODS AND MATERIALS: A total of 109 patients diagnosed with Parotid Gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100-120 Gy. After 6-24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria. The strength of correlation between the scores and the interobserver variability were calculated. RESULTS: Of 109 patients, 22.9% had telangiectasia; 78.9%, pigmentation; 28.4%, fibrosis; 4.6%, edema; 0.9%, ulceration; 37.6%, retraction and/or atrophy; 22.9%, sensation change; and 11%, scaliness and/or roughness. Compared with RTOG, LENT-SOMA criteria resulted in the upgrading of pigmentation in 17% of cases, the downgrading of all instances of telangiectasia and the downgrading of one instance of Grade 4 ulceration to Grade 3. Between the two scales, fibrosis and atrophy correlated well (Spearman p, 0.992, 0.986). An additional 229 side effects were observed using LENT-SOMA criteria. CONCLUSIONS: The LENT-SOMA scale was more accurate than the RTOG scale for the evaluation of late skin and subcutaneous toxicity. The downgrading of telangiectasia and upgrading of pigmentation with the LENT-SOMA scale reflected the patients' conditions better than the scores obtained with the RTOG scale. The assessment of fibrosis and atrophy correlated well between the two scales. The use of the sum of the individual scores of the LENT-SOMA is therefore advocated. The addition of decreased sweating and the removal of the alopecia (scalp) metric should be considered to standardize the reporting of late radiation morbidity. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.SCI(E)ARTICLE4,SI877-8831

Zhang Jie - One of the best experts on this subject based on the ideXlab platform.

  • Comparing the RTOG/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after I-125 seed brachytherapy for Parotid Gland Cancer
    BRACHYTHERAPY, 2017
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zhang Jie, Feng Zhien, Li Hua, Qin Li-zheng, Li Jian-hua, Huang Xin, Xing Ru-dong, Han Zheng-xue
    Abstract:

    PURPOSE: The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in Parotid Gland Cancer patients. METHODS AND MATERIALS: A total of 109 patients diagnosed with Parotid Gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100-120 Gy. After 6-24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria. The strength of correlation between the scores and the interobserver variability were calculated. RESULTS: Of 109 patients, 22.9% had telangiectasia; 78.9%, pigmentation; 28.4%, fibrosis; 4.6%, edema; 0.9%, ulceration; 37.6%, retraction and/or atrophy; 22.9%, sensation change; and 11%, scaliness and/or roughness. Compared with RTOG, LENT-SOMA criteria resulted in the upgrading of pigmentation in 17% of cases, the downgrading of all instances of telangiectasia and the downgrading of one instance of Grade 4 ulceration to Grade 3. Between the two scales, fibrosis and atrophy correlated well (Spearman p, 0.992, 0.986). An additional 229 side effects were observed using LENT-SOMA criteria. CONCLUSIONS: The LENT-SOMA scale was more accurate than the RTOG scale for the evaluation of late skin and subcutaneous toxicity. The downgrading of telangiectasia and upgrading of pigmentation with the LENT-SOMA scale reflected the patients' conditions better than the scores obtained with the RTOG scale. The assessment of fibrosis and atrophy correlated well between the two scales. The use of the sum of the individual scores of the LENT-SOMA is therefore advocated. The addition of decreased sweating and the removal of the alopecia (scalp) metric should be considered to standardize the reporting of late radiation morbidity. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.SCI(E)ARTICLE4,SI877-8831

  • The incidence of radioepidermitis and the dose-response relationship in Parotid Gland Cancer patients treated with 125I seed brachytherapy
    strahlentherapie und onkologie, 2015
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zheng Lei, Gao Hong, Zhang Jie, Liu Shu-ming, Huang Ming-wei, Shi Yan
    Abstract:

    Background We studied the incidence and dose-response relationship of radioepidermitis in Parotid Gland carcinoma patients treated with [I-125] seed brachytherapy in the hopes of designing an optimized pre-implant treatment plan that would reduce the incidence and severity of radioepidermitis in patients receiving this therapy. Patients and methods Between January 2007 and May 2010, 100 Parotid Gland Cancer patients were treated postoperatively with [I-125] seed brachytherapy. The matched peripheral dose (MPD) was 80-140 Gy, and [I-125] seed activity was 0.7-0.8 mCi. The mean dose delivered to the skin was calculated in the post-implant CT on day 0 following implantation. Grades of acute and late dermatitis were evaluated at 2, 6, 12, and 18 months post-implantation. Results Most patients experienced grade 0-2 acute and late skin side effects (86 and 97 %, respectively), though a small subset developed severe complications. Most grade 1-3 effects resolved within 6 months of implantation, though some grade 1-3 effects and all grade 4 effects remained unchanged throughout the 18-month follow-up period. Grade 3 and 4 effects were most prominent (75 and 25 %, respectively) with doses of 110-140 Gy; doses higher than 140 Gy produced only grade 4 effects. Conclusion [I-125] seed brachytherapy produced acceptable levels of acute and late radioepidermitis with a good clinical outcome. A mean dose under 100 Gy delivered to the skin was safe, though doses of 110-140 Gy should be given with caution and extra monitoring; doses greater than 140 Gy are dangerous and likely to produce grade 4-5 effects.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000347719800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701OncologyRadiology, Nuclear Medicine & Medical ImagingSCI(E)PubMed0ARTICLErszhang@126.com126-3319

Zhang Jian-guo - One of the best experts on this subject based on the ideXlab platform.

  • Comparing the RTOG/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after I-125 seed brachytherapy for Parotid Gland Cancer
    BRACHYTHERAPY, 2017
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zhang Jie, Feng Zhien, Li Hua, Qin Li-zheng, Li Jian-hua, Huang Xin, Xing Ru-dong, Han Zheng-xue
    Abstract:

    PURPOSE: The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in Parotid Gland Cancer patients. METHODS AND MATERIALS: A total of 109 patients diagnosed with Parotid Gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100-120 Gy. After 6-24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria. The strength of correlation between the scores and the interobserver variability were calculated. RESULTS: Of 109 patients, 22.9% had telangiectasia; 78.9%, pigmentation; 28.4%, fibrosis; 4.6%, edema; 0.9%, ulceration; 37.6%, retraction and/or atrophy; 22.9%, sensation change; and 11%, scaliness and/or roughness. Compared with RTOG, LENT-SOMA criteria resulted in the upgrading of pigmentation in 17% of cases, the downgrading of all instances of telangiectasia and the downgrading of one instance of Grade 4 ulceration to Grade 3. Between the two scales, fibrosis and atrophy correlated well (Spearman p, 0.992, 0.986). An additional 229 side effects were observed using LENT-SOMA criteria. CONCLUSIONS: The LENT-SOMA scale was more accurate than the RTOG scale for the evaluation of late skin and subcutaneous toxicity. The downgrading of telangiectasia and upgrading of pigmentation with the LENT-SOMA scale reflected the patients' conditions better than the scores obtained with the RTOG scale. The assessment of fibrosis and atrophy correlated well between the two scales. The use of the sum of the individual scores of the LENT-SOMA is therefore advocated. The addition of decreased sweating and the removal of the alopecia (scalp) metric should be considered to standardize the reporting of late radiation morbidity. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.SCI(E)ARTICLE4,SI877-8831

  • The incidence of radioepidermitis and the dose-response relationship in Parotid Gland Cancer patients treated with 125I seed brachytherapy
    strahlentherapie und onkologie, 2015
    Co-Authors: Mao Ming-hui, Zhang Jian-guo, Zheng Lei, Gao Hong, Zhang Jie, Liu Shu-ming, Huang Ming-wei, Shi Yan
    Abstract:

    Background We studied the incidence and dose-response relationship of radioepidermitis in Parotid Gland carcinoma patients treated with [I-125] seed brachytherapy in the hopes of designing an optimized pre-implant treatment plan that would reduce the incidence and severity of radioepidermitis in patients receiving this therapy. Patients and methods Between January 2007 and May 2010, 100 Parotid Gland Cancer patients were treated postoperatively with [I-125] seed brachytherapy. The matched peripheral dose (MPD) was 80-140 Gy, and [I-125] seed activity was 0.7-0.8 mCi. The mean dose delivered to the skin was calculated in the post-implant CT on day 0 following implantation. Grades of acute and late dermatitis were evaluated at 2, 6, 12, and 18 months post-implantation. Results Most patients experienced grade 0-2 acute and late skin side effects (86 and 97 %, respectively), though a small subset developed severe complications. Most grade 1-3 effects resolved within 6 months of implantation, though some grade 1-3 effects and all grade 4 effects remained unchanged throughout the 18-month follow-up period. Grade 3 and 4 effects were most prominent (75 and 25 %, respectively) with doses of 110-140 Gy; doses higher than 140 Gy produced only grade 4 effects. Conclusion [I-125] seed brachytherapy produced acceptable levels of acute and late radioepidermitis with a good clinical outcome. A mean dose under 100 Gy delivered to the skin was safe, though doses of 110-140 Gy should be given with caution and extra monitoring; doses greater than 140 Gy are dangerous and likely to produce grade 4-5 effects.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000347719800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701OncologyRadiology, Nuclear Medicine & Medical ImagingSCI(E)PubMed0ARTICLErszhang@126.com126-3319